Orthonotes
Orthonotes
by the.bonestories
v3.5 Fusion Pro
v3.5 Fusion Pro
PubMed Guideline / Consensus Evidence High

Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium.

Frontiers in endocrinology | 2021 | Laurent MR, De Schepper J, Trouet D, Godefroid N

In-App Reader

Open Source

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Source
PubMed
Type
Guideline / Consensus
Evidence
High

Abstract

[Indexed for MEDLINE] Conflict of interest statement: ML has received lecture and consultancy fees from Alexion, Amgen, Kyowa Kirin, Menarini, Sandoz, Takeda, UCB and Will-Pharma. JS has received lecture, consultancy fees, and conference support from Kyowa Kirin, Alexion, Eli-Lily, Ferring, Ipsen, Menarini, Novo Nordisk, Pfizer, Sandoz, and Siemens Healthcare. DT has received conference support from Novo Nordisk. NG, JLa, and KH have received consultancy fees from Kyowa Kirin. EB has received conference support from Novo Nordisk and Pfizer. CH has received consultancy fees and conference support from Kyowa Kirin, Novo Nordisk, and Ferring. EC has received consultancy fees from bioMérieux, Diasorin, Fujirebio, IDS, and Menarini. PH is an employee of GlaxoSmithKline but participates in his own capacity. J-FK has received consultancy fees and conference support from Heel Belgium, Sanofi, and TRB Chemedica. KW has received conference support from Alexion, Ferring, Kyowa Kirin and Novo Nordisk. CV has received conference support from Boehringer Ingelheim. GM has received consultancy fees from Alexion, Biomarin, Kyowa Kirin, and Pfizer. EL has received consultancy fees and travel support from Kyowa Kirin, Chiesi, and Recordati. JV has received conference support and consultancy fees from Alexion, Bellco, Ferring, Medtronic, and Kyowa Kirin. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. 14. Orthop Clin North Am. 2019 Apr;50(2):181-191. doi: 10.1016/j.ocl.2018.10.002. The Role of Vitamin D in Pediatric Orthopedics. Horan MP(1), Williams K(2), Hughes D(2). Author information: (1)Pediatric Orthopaedic Surgery, Palmetto Health-USC Orthopaedic Center, University of South Carolina, 14 Medical Park, Suite 200, Columbia, SC 29203, USA. Electronic address: michael.horan@palmettohealth.org. (2)Department of Orthopaedic Surgery, University of South Carolina School of Medicine, Medical Park 2, Suite 400, Columbia, SC 29203, USA. Understanding the role of vitamin D is an important component of the proper care of the pediatric orthopedic patient. Vitamin D is an essential component of bone metabolism in the growth and development of the pediatric skeleton, which can be acutely affected by changes to the body's vitamin D, calcium, and phosphate levels, resulting in pathologic conditions such as rickets or fractures. This article reviews the main areas in which vitamin D relates to pediatric orthopedics and highlights some of the areas where future research is being directed. Copyright © 2018 Elsevier Inc. All rights reserved. DOI: 10.1016/j.ocl.2018.10.002

Linked Wiki Topics

This article has not been linked to a wiki topic yet.

Linked Cases

This article has not been linked to a case yet.

Linked Atlases

This article has not been linked to an atlas yet.